论文部分内容阅读
目的检测MAGE-A9在乳腺癌中的表达情况,分析其与乳腺癌临床病理特征的关系。方法在组织芯片上(70例乳腺癌标本及20例癌旁对照标本)进行免疫组化检测,使用Cox回归法及Kaplan-Meier生存分析法进行乳腺癌病人的预后评估。结果免疫组化结果显示乳腺癌中的MAGE-A9表达明显高于癌旁对照组的表达(P<0.05)。MAGE-A9的表达与乳腺癌病人的肿瘤组织学分级、淋巴结转移、远处转移及TNM分期有重要关联(P均<0.05)。生存分析显示MAGE-A9阳性、TNM分期与乳腺癌病人预后关系密切,MAGE-A9高表达提示病人预后不良。结论 MAGE-A9在乳腺癌组织中异常高表达且MAGE-A9的表达与乳腺癌病人的多项重要临床指标相关。MAGE-A9可作为乳腺癌病人预后的独立危险因素。
Objective To detect the expression of MAGE-A9 in breast cancer and analyze its relationship with the clinicopathological features of breast cancer. Methods Immunohistochemistry was performed on tissue microarray (70 breast cancer specimens and 20 adjacent normal tissues). The prognosis of breast cancer patients was assessed by Cox regression and Kaplan-Meier survival analysis. Results The results of immunohistochemistry showed that the expression of MAGE-A9 in breast cancer was significantly higher than that in adjacent non-cancerous tissues (P <0.05). The expression of MAGE-A9 was correlated with histological grade, lymph node metastasis, distant metastasis and TNM stage in breast cancer patients (all P <0.05). Survival analysis showed that MAGE-A9 positive, TNM stage is closely related to the prognosis of breast cancer patients, high expression of MAGE-A9 prompted poor prognosis. Conclusion MAGE-A9 is highly expressed in breast cancer tissues and the expression of MAGE-A9 is associated with a number of important clinical indicators in patients with breast cancer. MAGE-A9 can be used as an independent risk factor for the prognosis of breast cancer patients.